Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Valentini

Showing results (121-130 of 143) with videos related to

Pageof 15
Sort By:
Annals of the Rheumatic Diseases|October 25, 2014
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective studyMuriel Elhai, Jérôme Avouac, Ulrich A Walker, et al.
Annals of the Rheumatic Diseases|September 14, 2016
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity indexGabriele Valentini, Michele Iudici, Ulrich A Walker, et al.
Journal of Autoimmunity|April 10, 2009
Prevalence of hepatitis C serum antibody in autoimmune diseasesNancy Agmon-Levin, Maya Ram, Ori Barzilai, et al.
Annals of the Rheumatic Diseases|August 19, 2019
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrualSerena Fasano, Antonella Riccardi, Valentina Messiniti, et al.
Arthritis and Rheumatism|April 11, 2012
Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunityEugénie Koumakis, Matthieu Giraud, Philippe Dieudé, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 22, 2018
Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group StudyVeronika K Jaeger, Gabriele Valentini, Eric Hachulla, et al.
Annals of the Rheumatic Diseases|February 3, 2011
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma researchChristian Beyer, Jörg H W Distler, Yannick Allanore, et al.
Rheumatology (Oxford, England)|November 5, 2019
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group studyVeronika K Jaeger, Mohammed Tikly, Dong Xu, et al.
The Journal of Rheumatology|July 6, 2007
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA studyLuana Mancarella, Francesca Bobbio-Pallavicini, Fulvia Ceccarelli, et al.
Seminars in Arthritis and Rheumatism|October 1, 2011
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entitySusanna Cappelli, Silvia Bellando Randone, Dušanka Martinović, et al.
Pageof 15

Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
Annals of the Rheumatic Diseases|October 25, 2014
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective studyMuriel Elhai, Jérôme Avouac, Ulrich A Walker, et al.
Annals of the Rheumatic Diseases|September 14, 2016
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity indexGabriele Valentini, Michele Iudici, Ulrich A Walker, et al.
Journal of Autoimmunity|April 10, 2009
Prevalence of hepatitis C serum antibody in autoimmune diseasesNancy Agmon-Levin, Maya Ram, Ori Barzilai, et al.
Annals of the Rheumatic Diseases|August 19, 2019
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrualSerena Fasano, Antonella Riccardi, Valentina Messiniti, et al.
Arthritis and Rheumatism|April 11, 2012
Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunityEugénie Koumakis, Matthieu Giraud, Philippe Dieudé, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 22, 2018
Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group StudyVeronika K Jaeger, Gabriele Valentini, Eric Hachulla, et al.
Annals of the Rheumatic Diseases|February 3, 2011
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma researchChristian Beyer, Jörg H W Distler, Yannick Allanore, et al.
Rheumatology (Oxford, England)|November 5, 2019
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group studyVeronika K Jaeger, Mohammed Tikly, Dong Xu, et al.
The Journal of Rheumatology|July 6, 2007
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA studyLuana Mancarella, Francesca Bobbio-Pallavicini, Fulvia Ceccarelli, et al.
Seminars in Arthritis and Rheumatism|October 1, 2011
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entitySusanna Cappelli, Silvia Bellando Randone, Dušanka Martinović, et al.
Pageof 15